MircroPort Medbot-B

2252
21.1800.00% ( 0.000 )
Delay Suspended: Nov 16, 09:29:28

Overview

MircroPort Medbot-B (2252)

Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, manufacturing, and sale of surgical robots in the People’s Republic of Chin...

Open
21.180
High
21.180
Low
21.180
Prev. Close
21.180
Volume
0
Turnover
0
Avg Price
--
Bid/Ask Ratio
--
Amplitude
0.00%
52wk High
35.340
Volume Ratio
0.00
Turnover Ratio
--
52wk Low
19.640
HK Mkt Cap
21.83B
Market CapHKD
21.84B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.268
EPSDynamic
-0.268
EPSStatic
--
BVPS
0.44
P/B
48.04
HK Shares
1.03B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.03B
Min lot size
500
Currency
HKD

MircroPort Medbot-B Analyst Rating

View more

Forecast & Rating

Oct 26, 2026
Price forecast
HK$36.4772.19%
Forecast & RatingStrong buy
10analysts
  • Strong buy70.00%
  • Buy20.00%
  • Hold10.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Aug, 31

    MicroPort MedBot-B (2252.HK) opened sharply lower and trended downward in the morning session, closing at 09:49 BJ at HK$20.86, down 5.18%, with the intraday low at HK$20.86 and the open at HK$22.00 marking the session high, forming a surge-and-retreat pattern. The decline was driven by concerns over corporate governance after the company postponed its board meeting to review interim results and announced the resignation of executive director Yu Liu, dampening the optimism from its first-ever semi-annual profit guidance (forecasted net profit for 1H 2026). On the earnings front, Q4 2025 revenue surged 148.32% YoY to HK$208.7 million, while net loss narrowed 60.99% YoY, indicating solid operational improvement. However, the current price of HK$20.86 remains well below its 20-day MA of HK$23.48 and 60-day MA of HK$23.21, and is 40.97% below its 52-week high of HK$35.34, with a high PB ratio of 47.32x, reflecting persistent market skepticism about profitability sustainability. While the net profit margin narrowed to -36.31% in Q4 2025, a sustained earnings turnaround could provide a floor for the stock.

  2. Aug, 28

    MicroPort MedBot-B (2252.HK) experienced a morning session surge and retreat, hitting an intraday high of HK$22.90 before retreating to HK$21.74, down approximately 4.4% with an intraday range of 5.1%. Recent governance enhancements—including the formation of an ESG committee and a subsidiary's RMB 20.92 million finance lease exit to secure prototype ownership—were overshadowed by lingering investor focus on the company's first-half 2026 profit guidance. Q4 2025 revenue surged 148.32% YoY to HK$208.7 million, while net loss narrowed 60.99% to HK$75.8 million, indicating a clear fundamental improvement. However, the current price of HK$21.74 remains below the 20-day MA of HK$23.484 and 60-day MA of HK$23.265, 38.5% below the 52-week high of HK$35.34, and down 11.13% year-to-date, reflecting market uncertainty over earnings sustainability.

  3. Aug, 24

    MicroPort MedBot-B slid sharply in the morning session, opening at HKD 23.54 and hitting an intraday high of HKD 23.74 before falling in a single downward trend to HKD 22.56, down 5.05%. The stock is now 36.16% below its 52-week high of HKD 35.34 and trades below both its 20-day MA (HKD 23.116) and 60-day MA (HKD 23.443), with a YTD decline of 7.69%. Recent guidance for a first-half net profit of HKD 28M-40M, reversing a prior-year loss, and a Citi Buy rating were likely already priced in, prompting profit-taking. However, Q4 2025 revenue surged 148.32% YoY and net loss narrowed 60.99%, underpinning the core surgical robot sales momentum.

  4. Aug, 20

    MicroPort MedBot opened sharply higher and trended steadily upward during the morning session, climbing from its opening price of HK$23.92 to a high of HK$24.52, representing a gain of 4.79% on turnover of approximately HK$14 million. The company had previously guided for its first-ever semi-annual net profit of RMB 28 million to RMB 40 million, and Q4 revenue surged 148.32% YoY to HK$209 million while net loss narrowed 60.99% YoY, reinforcing the turnaround narrative. However, the stock still trades well below its 52-week high and carries a price-to-book ratio of 55.62x, reflecting elevated valuation during a loss-making period, which may cap further upside.

  5. Aug, 19

    MicroPort MedBot opened lower and continued to slide in the morning session of Hong Kong stock market, closing at HKD 23.52, down 5.24%, and hitting an intraday low of HKD 23.52. The decline was mainly driven by profit-taking after the previous session's sharp rally, which followed the company's first-ever semi-annual net profit guidance of RMB 28-40 million for H1 2025, a significant turnaround from a loss in the same period last year. Revenue in the first half surged over 130% year-on-year, with Q4 and Q3 revenue growth of 148% and 134% respectively, yet the company remains loss-making, with operating profit still negative. The current price of HKD 23.52 is 33.45% below the 52-week high of HKD 35.34 and below the 60-day moving average of HKD 23.607, but just above the 20-day MA of HKD 22.749, suggesting short-term support with medium-term resistance. However, the narrowing loss trajectory and the recent EU CE Mark certification for its products may support the stock in the near term.

News

Bullish vs. Bearish — Last 3 Months

8.1k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • S
    SG Visual Research

    China Robotics Watch: From Factory Deployment to Eldercare

    $UBTECH ROBOTICS(09880.HK) $MircroPort Medbot-B(02252.HK) $AJJ Medtech(584.SG) Robotics is moving from technical demos into real-world deployment.From a China market perspective, robotics is not a single-company story. It is a mul...

    China Robotics Watch: From Factory Deployment to Eldercare 中国机器人观察: 从工厂落地到养老护理 TLong image
    The STI Slipped. Industrial REITs Led Losses.